- Home
- MARPS vs GTBP Comparison
MARPS vs GTBP Comparison
Compare MARPS & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MARPS | GTBP |
|---|---|---|
| Founded | 1956 | 1965 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9M | 8.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MARPS | GTBP |
|---|---|---|
| Price | $5.00 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.7K | ★ 681.2K |
| Earning Date | 02-13-2026 | 05-15-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | N/A | ★ 3.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.70 | $0.26 |
| 52 Week High | $6.49 | $3.73 |
Technical Indicators
Market Signals| Indicator | MARPS | GTBP |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 39.00 |
| Support Level | $4.17 | $0.26 |
| Resistance Level | $5.06 | $0.48 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 45.92 | 33.14 |
Price Performance
Historical ComparisonAbout MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.